Respiratory Bacterial infections cause mild to severe diseases worldwide, such as pharyngitis, sinusitis, bronchitis, bronchiolitis and pneumonia, are associated with huge costs for society. To test new molecules for shortening, alleviating the diseases or to develop new therapies, relevant human models are mandatory. MucilAir™ and SmallAir™, holds in vitro specific mechanisms to counter invaders comparable to the in vivo situation, such as mucus production, mucociliary clearance, and secretion of defensive molecules.
Pseudomonas Aeruginosa![]() |
Streptococcus Pneumoniae![]() |
Staphylococcus Aureus![]() |
Haemophilus Influenzae![]() |
PA growth is slightly inhibited by presence of Mucus as efficiently inhibited by Meronem treatment.
Mucus seemed to prevent cytotoxicity induced by PA up to 72h. Meronem prevented cytotoxicity induced by PA up to 72h
PA impaired the barrier function from 48h post inoculation without mucus. Presence of mucus protect the barrier function up to 48h. Meronem efficiently preserved the barrier function from PA infection at all tested time points.
More information: Please contact